Linguistic markers predict onset of Alzheimer's disease

被引:91
|
作者
Eyigoz, Elif [1 ]
Mathur, Sachin [2 ]
Santamaria, Mar [2 ]
Cecchi, Guillermo [1 ]
Naylor, Melissa [2 ]
机构
[1] IBM Res, IBM Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA
[2] Pfizer Worldwide Res & Dev, Cambridge, MA 02139 USA
关键词
MILD COGNITIVE IMPAIRMENT; LATE-LIFE; FRAMINGHAM; DEMENTIA; RISK; COMPREHENSION; PERFORMANCE; BREAKDOWN; PATTERNS; LANGUAGE;
D O I
10.1016/j.eclinm.2020.100583
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of this study is to use classification methods to predict future onset of Alzheimer's disease in cognitively normal subjects through automated linguistic analysis. Methods: To study linguistic performance as an early biomarker of AD, we performed predictive modeling of future diagnosis of AD from a cognitively normal baseline of Framingham Heart Study participants. The linguistic variables were derived from written responses to the cookie-theft picture-description task. We compared the predictive performance of linguistic variables with clinical and neuropsychological variables. The study included 703 samples from 270 participants out of which a dataset consisting of a single sample from 80 participants was held out for testing. Half of the participants in the test set developed AD symptoms before 85 years old, while the other half did not. All samples in the test set were collected during the cognitively normal period (before MCI). The mean time to diagnosis of mild AD was 7.59 years. Findings: Significant predictive power was obtained, with AUC of 0.74 and accuracy of 0.70 when using linguistic variables. The linguistic variables most relevant for predicting onset of AD have been identified in the literature as associated with cognitive decline in dementia. Interpretation: The results suggest that language performance in naturalistic probes expose subtle early signs of progression to AD in advance of clinical diagnosis of impairment. (C) 2020 Published by Elsevier Ltd.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Sporadic early-onset Alzheimer's disease: a unique subtype of Alzheimer's disease
    Zhang, Zhentao
    CHINESE SCIENCE BULLETIN-CHINESE, 2025, 70 (01): : 6 - 7
  • [42] Neuroimaging to predict preclinical Alzheimer's disease
    Kumari, V
    Mitterschiffthaler, MT
    Sharma, T
    HOSPITAL MEDICINE, 2002, 63 (06): : 341 - 345
  • [43] Using Biomarkers to Predict Alzheimer's disease?
    Feldmann, Christoph
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 (38) : 1858 - 1858
  • [44] Preclinical memory markers of Alzheimer's disease
    Rogers, S. A.
    Miller, K. J.
    Dejong, J.
    Ercoli, L.
    Siddarth, P.
    Small, G.
    CLINICAL NEUROPSYCHOLOGIST, 2006, 20 (03) : 598 - 599
  • [45] Biological markers and the treatment of Alzheimer’s Disease
    Douglas Galasko
    Journal of Molecular Neuroscience, 2001, 17 : 119 - 125
  • [46] Olfactory markers of depression and Alzheimer's disease
    Marine, Naudin
    Boriana, Atanasova
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2014, 45 : 262 - 270
  • [47] Peripheral biochemical markers in Alzheimer's disease
    Pivac, N
    Mueck-Seler, D
    Mustapic, M
    Mimica, N
    Sagud, M
    Folnegovic-Smalc, V
    Mihaljevic-Peles, A
    Jakovljevic, M
    EUROPEAN PSYCHIATRY, 2004, 19 : 152S - 152S
  • [48] Biological markers for the diagnosis of Alzheimer's disease
    Bancher, C
    Jellinger, K
    Wichart, I
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1998, (53): : 185 - 197
  • [49] Biological markers and the treatment of Alzheimer's disease
    Galasko, D
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2001, 17 (02) : 119 - 125
  • [50] Examining vascular markers in Alzheimer's Disease
    Bearer, E.
    Ranjbar, M.
    Sanchex, K.
    Martinez, C.
    Yang, Y.
    Keene, C.
    Rosenberg, G.
    SantaCruz, K.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 572 - 572